Cytomegalovirus upregulates vascular endothelial growth factor and its second cellular kinase domain receptor in human fibroblasts

Viral Immunology

Volumn 25, Issue 5, 2012, Pages 360-367

  Heiske, Andreas ^a   Roettger, Yvonne ^a   Bacher, Michael ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; UPREGULATION; VIRUS STRAIN; WESTERN BLOTTING;

BASE SEQUENCE; CELL LINE; CYTOMEGALOVIRUS; FIBROBLASTS; GRAFT REJECTION; HUMANS; RNA, MESSENGER; SEQUENCE ANALYSIS, DNA; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTORS;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

EID: 84867228876     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2012.0028     Document Type: Article

References (32)

1. Bacher M, Eickmann M, Schrader J, Gemsa D, and Heiske A: Human cytomegalovirus-mediated induction of MIF in fibroblasts. Virology 2002;299:32-37.
2. Bellamy WT, Richter L, Sirjani D, et al.: Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001; 97:1427-1434.
3. Bock F, Onderka J, Dietrich T, Bachmann B, Pytowski B, and Cursiefen C: Blockade of VEGFR3-signalling specifically inhibits lymphangiogenesis in inflammatory corneal neovascularisation. Graefes Arch Clin Exp Ophthalmol 2008; 246:115-119.
4. Borchers AT, Perez R, Kaysen G, Ansari AA, and Gershwin ME: Role of cytomegalovirus infection in allograft rejection: a review of possible mechanisms. Transpl Immunol 1999; 7:75-82.
5. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, and Dake MD: Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001;7: 425-429.
6. Cursiefen C, Cao J, Chen L, et al.: Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 2004;45:2666-26673.
7. Dias S, Hattori K, Zhu Z, et al.: Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000;106:511-521.
8. Ferrara N, Houck K, Jakeman L, and Leung DW: Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992;13:18-32.
9. Geist LJ, and Dai LY: Cytomegalovirus modulates interleukin-6 gene expression. Transplantation 1996;62:653-658.
10. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, and Shumway NE: Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989;261:3561-3566.
11. Hodson EM, Jones CA, Webster AC, et al.: Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005;365:2105-2115.
12. Holmes K, Roberts OL, Thomas AM, and Cross MJ: Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 2007;19:2003-2012.
13. Huang ES: Human cytomegalovirus. IV. Specific inhibition of virus-induced DNA polymerase activity and viral DNA replication by phosphonoacetic acid. J Virol 1975;16:1560-1565.
14. Humar A, Limaye AP, Blumberg EA, et al.: Extended valganciclovir prophylaxis in D kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation 2010;90:1427-1431.
15. Lan HY, Yang N, Brown FG, et al.: Macrophage migration inhibitory factor expression in human renal allograft rejection. Transplantation 1998;66:1465-1471.
16. Lemstrom KB, Krebs R, Nykanen AI, et al.: Vascular endothelial growth factor enhances cardiac allograft arteriosclerosis. Circulation 2002;105:2524-2530.
17. Neufeld G, Tessler S, Gitay-Goren H, Cohen T, and Levi BZ: Vascular endothelial growth factor and its receptors. Prog Growth Factor Res 1994;5:89-97.
18. Radsak K, Brucher KH, Britt W, Shiou H, Schneider D, and Kollert A: Nuclear compartmentation of glycoprotein B of human cytomegalovirus. Virology 1990;177:515-522.
19. Raisky O, Nykanen AI, Krebs R, et al.: VEGFR-1 and-2 regulate inflammation, myocardial angiogenesis, and arteriosclerosis in chronically rejecting cardiac allografts. Arterioscler Thromb Vasc Biol 2007;27:819-825.
20. Rak J, Mitsuhashi Y, Bayko L, et al.: Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995; 55:4575-4580.
21. Reinders ME, Sho M, Izawa A, et al.: Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Invest 2003;112:1655-1665.
22. Reinhardt B, Schaarschmidt P, Bossert A, et al.: Upregulation of functionally active vascular endothelial growth factor by human cytomegalovirus. J Gen Virol 2005;86:23-30.
23. Rintala SE, Savikko J, Rintala JM, and von Willebrand E: Vascular endothelial growth factor (VEGF) ligand and receptor induction in rat renal allograft rejection. Transplant Proc 2006;38:3236-3238.
24. Rubin RH, Tolkoff-Rubin NE, Oliver D, et al.: Multicenter seroepidemiologic study of the impact of cytomegalovirus infection on renal transplantation. Transplantation 1985;40: 243-249.
25. Shen BQ, Lee DY, Gerber HP, Keyt BA, Ferrara N, and Zioncheck TF: Homologous up-regulation of KDR/Flk-1 receptor expression by vascular endothelial growth factor in vitro. J Biol Chem 1998;273:29979-29985.
26. Shweiki D, Itin A, Soffer D, and Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-845.
27. Slifkin M, Ruthazer R, Freeman R, et al.: Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation. Liver Transpl 2005;11:1597-1602.
28. Stinski MF: Human cytomegalovirus: glycoproteins associated with virions and dense bodies. J Virol 1976;19:594-609.
29. Streblow DN, Orloff SL, and Nelson JA: Acceleration of allograft failure by cytomegalovirus. Curr Opin Immunol 2007;19:577-582.
30. Tammela T, Enholm B, Alitalo K, and Paavonen K: The biology of vascular endothelial growth factors. Cardiovasc Res 2005;65:550-563.
31. Varani S, and Landini MP: Cytomegalovirus-induced immunopathology and its clinical consequences. Herpesviridae 2011;2: 6.
32. Weisz A, Koren B, Cohen T, et al.: Increased vascular endothelial growth factor 165 binding to kinase insert domaincontaining receptor after infection of human endothelial cells by recombinant adenovirus encoding the Vegf(165) gene. Circulation 2001;103:1887-1892.